SART3 and hepatocellular carcinoma: Our study reveals that high and low SART3 expression levels can be used to select potentially responsive HCC therapeutic agents, including sorafenib, bortezomib, and oxaliplatin [44] (a first-line HAIC therapeutic agent for advanced HCC).